MedTrace Logo

Dendritic Cell Vaccine in HIV-1 Infection

NCT00402142 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-02-26

No results posted yet for this study

Summary

1. To study the efficacy of a therapeutic HIV vaccine consisting of autologous myeloid dendritic cells pulsed ex vivo with high doses of inactivated autologous HIV-1, in HIV-1 infected patients in a very early stages of the disease (CD4 \> 450 x 10 6 /L).
2. To analyze the HIV-1 humoral and cellular immune responses induced by this immune-based therapy.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

Dendritic cell vaccine

107 DC subcutaneous 3 doses every 2 weeks

BIOLOGICAL

non pulsed dendritic cell untreated patients

107 DC subcutaneous 3 doses every 2 weeks

BIOLOGICAL

pulsed dendritic cell vaccine

107 DC subcutaneous 3 doses every 2 weeks

BIOLOGICAL

dendritic cell vaccine

107 DC subcutaneous 3 doses every 2 weeks

BIOLOGICAL

non pulsed dendritic cell vaccine

107 DC subcutaneous 3 doses every 2 weeks

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Felipe García, MD, PhD · Hospital Clínic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00402142 on ClinicalTrials.gov